Search details
1.
Beneficial Impact of Eicosapentaenoic Acid on the Adverse Effects Induced by Palmitate and Hyperglycemia on Healthy Rat Chondrocyte.
Int J Mol Sci
; 25(3)2024 Feb 02.
Article
in English
| MEDLINE | ID: mdl-38339087
2.
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.
J Card Fail
; 28(5): 778-786, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34933097
3.
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Eur Heart J
; 42(6): 684-696, 2021 02 11.
Article
in English
| MEDLINE | ID: mdl-33215209
4.
Selective involvement of serum response factor in pressure-induced myogenic tone in resistance arteries.
Arterioscler Thromb Vasc Biol
; 33(2): 339-46, 2013 Feb.
Article
in English
| MEDLINE | ID: mdl-23264443
5.
Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss.
Nat Genet
; 37(4): 418-22, 2005 Apr.
Article
in English
| MEDLINE | ID: mdl-15735644
6.
A new pyrroline compound selective for I1-imidazoline receptors improves metabolic syndrome in rats.
J Pharmacol Exp Ther
; 346(3): 370-80, 2013 Sep.
Article
in English
| MEDLINE | ID: mdl-23818682
7.
Response to: 'Spontaneous hypertensive rat exhibits bone and meniscus phenotypes of osteoarthritis: is it an appropriate control for MetS-associated OA?' by Chan and Wen.
Ann Rheum Dis
; 77(5): e26, 2018 05.
Article
in English
| MEDLINE | ID: mdl-28988205
8.
Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis.
Ann Rheum Dis
; 77(2): 315-316, 2018 02.
Article
in English
| MEDLINE | ID: mdl-28476879
9.
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study.
Circ Heart Fail
; 16(5): e009694, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37192292
10.
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
JACC Heart Fail
; 9(4): 268-277, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33549556
11.
Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses.
Clin Res Cardiol
; 109(1): 22-33, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31062082
12.
Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.
Heart
; 105(4): 307-314, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30121630
13.
Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.
Circ Heart Fail
; 12(5): e005897, 2019 05.
Article
in English
| MEDLINE | ID: mdl-31104495
14.
Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease.
J Mol Cell Cardiol
; 44(2): 293-303, 2008 Feb.
Article
in English
| MEDLINE | ID: mdl-18182166
15.
Connexin 40, a target of transcription factor Tbx5, patterns wrist, digits, and sternum.
Mol Cell Biol
; 25(12): 5073-83, 2005 Jun.
Article
in English
| MEDLINE | ID: mdl-15923624
16.
Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis.
ESC Heart Fail
; 5(1): 139-148, 2018 02.
Article
in English
| MEDLINE | ID: mdl-28988439
17.
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
Eur J Heart Fail
; 19(8): 974-986, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28401618
18.
Myocardial fibrosis: biomedical research from bench to bedside.
Eur J Heart Fail
; 19(2): 177-191, 2017 02.
Article
in English
| MEDLINE | ID: mdl-28157267
19.
The Multifaceted Role of the Lysosomal Protease Cathepsins in Kidney Disease.
Front Cell Dev Biol
; 5: 114, 2017.
Article
in English
| MEDLINE | ID: mdl-29312937
20.
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
Eur J Heart Fail
; 19(9): 1186-1197, 2017 09.
Article
in English
| MEDLINE | ID: mdl-28303624